The rapid identification of respiratory virus outbreaks is needed to enable rational and effective public health interventions. We developed new quantitative approaches for simultaneous ...

As many as 20 people developed a potentially paralysing illness after getting the respiratory syncytial virus (RSV) vaccine.

Leading oncology centers in the United States engaged to conduct the Phase 2 Antiviral Trial and further advance the development of PUL-042 HOUSTON, TX, UNITED STATES, July 8, 2025 /EINPresswire.com/ ...

Test positivity for common cold coronaviruses significantly declined following widespread SARS-CoV-2 infection and COVID-19 ...

The CDC already recommends the RSV shot for all adults 75 and older and for people 60 and older who have health conditions that increase their risk of severe RSV.

Vermont has the second lowest state fatality rate in the US (148.3 per 100K; Hawaii 113.6/100K). Mississippi (465.9/100K) and ...

The ACIP is a federal advisory committee composed of medical and public health experts who make recommendations on the use of vaccines for adults and children in the US.

GSK has become the first pharma company to get regulatory approval for a vaccine against respiratory syncytial virus (RSV), setting up what looks set to be a highly lucrative – and likely ...

Passive immunisation for respiratory syncytial virus for infants is recommended by the World Health Organization but products currently available have limited duration of protection.